Strategy of the Global Leader in Rare Disease Drugs with Scott Pescatore Recordati

Scott Pescatore, Executive VP of the Rare Diseases Business at Recordati, is focused on rare and ultra-orphan diseases with high unmet needs by acquiring promising compounds from other companies and advancing them through development and approval. An example is the company's drug Isturisa, acquired from Novartis, which is an FDA-approved effective treatment for patients with Cushing syndrome, a rare endocrine condition. Raising awareness of rare diseases among physicians, patients, and the general public is a priority for Recordati to improve diagnosis rates and clinical trial participation, and to encourage more research and funding in the rare disease space.

Scott explains, "We have two primary divisions at Recordati. One is our specialty primary care business, and the other is the rare disease business, which I have the honor and privilege to look after. And we have a very simple sort of work ethic or business mantra, if you will, and that's focused on the few. And we really dedicate ourselves to focusing on disease areas and patient groups and therapeutic areas that have a high unmet need and really low or limited options for patients. And really focusing on diseases and areas that are rare and considered ultra-orphan by the definitions in the US, where really there's a very small patient base. And that's where we began back in 2007, when the rare disease business was formed. And that's really what our focus has been since then. And we continue to focus on this segment of the market."

"So Isturisa is really a fantastic product. We acquired this product through a deal we did with Novartis Pharmaceuticals back in 2019, and this product has FDA approval for patients who have endogenous hypercortisolemia with Cushing syndrome. So it's quite a nasty disease, but it's a very efficacious product. The product is what's considered a cortisol inhibitor in the blocks in a particular enzyme to help normalize hypercortisolemia in patients with Cushing syndrome. And Cushing syndrome, for those who aren't familiar, is a rare endocrine condition that really has a significant impact on patients' quality of life, on the caregivers, on the families. And the indication I mentioned was supported by quite robust phase 3 trials."

#Recordati #RareDisease #FocusedontheFew #CushingSyndrome #IMCD #CastlemansDisease

recordati.com

Download the transcript here